Analyst Ratings For Adaptimmune Therapeutics (NASDAQ:ADAP)
Today, Leerink Swann initiated coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy with a price target of $15.00.
Some recent analyst ratings include
- 3/16/2018-Leerink Swann initiated coverage with a Buy rating.
- 11/10/2017-SunTrust Banks Reiterated Rating of Buy.
- 6/6/2017-Cowen Reiterated Rating of Buy.
- 3/17/2017-Wells Fargo & Co initiated coverage with a Market Perform rating.
- 10/24/2016-Bank of America was Downgraded by analysts at Bank of America from a “Neutral ” rating to a ” Underperform” rating.
- 9/30/2016-Raymond James Financial initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Adaptimmune Therapeutics (NASDAQ:ADAP)
Adaptimmune Therapeutics (NASDAQ:ADAP) has insider ownership of 24.45% and institutional ownership of 55.58%.
- On 3/27/2017 Enterprise Associates 14 New, Major Shareholder, bought 12,870,000 with an average share price of $0.70 per share and the total transaction amounting to $9,009,000.00.
- On 3/27/2017 Orbimed Advisors Llc, Director, bought 1,190,476 with an average share price of $4.20 per share and the total transaction amounting to $4,999,999.20.
- On 5/24/2016 Orbimed Advisors Llc, Director, bought 1,712,400 with an average share price of $10.42 per share and the total transaction amounting to $17,843,208.00.
- On 5/19/2016 Charles Elliott Sigal, Director, bought 15,000 with an average share price of $1.56 per share and the total transaction amounting to $23,400.00.
- On 5/18/2016 Charles Elliott Sigal, Director, bought 45,000 with an average share price of $1.53 per share and the total transaction amounting to $68,850.00.
Recent Trading Activity for Adaptimmune Therapeutics (NASDAQ:ADAP)
Shares of Adaptimmune Therapeutics closed the previous trading session at with 310343 shares trading hands.